Clinical translation of pluripotent stem cell-based therapies : successes and challenges
(2024) In Development (Cambridge) 151(7).- Abstract
The translational stem cell research field has progressed immensely in the past decade. Development and refinement of differentiation protocols now allows the generation of a range of cell types, such as pancreatic β-cells and dopaminergic neurons, from human pluripotent stem cells (hPSCs) in an efficient and good manufacturing practice-compliant fashion. This has led to the initiation of several clinical trials using hPSC-derived cells to replace lost or dysfunctional cells, demonstrating evidence of both safety and efficacy. Here, we highlight successes from some of the hPSC-based trials reporting early signs of efficacy and discuss common challenges in clinical translation of cell therapies.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/ace8101d-0ec0-452e-b978-bd0f3b899155
- author
- Christiansen, Josefine Rågård and Kirkeby, Agnete LU
- organization
- publishing date
- 2024-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- ATMP, Cell therapy, Clinical trial, Human pluripotent stem cells, Transplantation
- in
- Development (Cambridge)
- volume
- 151
- issue
- 7
- article number
- dev202067
- publisher
- The Company of Biologists Ltd
- external identifiers
-
- scopus:85195545704
- pmid:38564308
- ISSN
- 0950-1991
- DOI
- 10.1242/dev.202067
- language
- English
- LU publication?
- yes
- id
- ace8101d-0ec0-452e-b978-bd0f3b899155
- date added to LUP
- 2024-08-30 13:31:56
- date last changed
- 2024-10-11 19:42:03
@article{ace8101d-0ec0-452e-b978-bd0f3b899155, abstract = {{<p>The translational stem cell research field has progressed immensely in the past decade. Development and refinement of differentiation protocols now allows the generation of a range of cell types, such as pancreatic β-cells and dopaminergic neurons, from human pluripotent stem cells (hPSCs) in an efficient and good manufacturing practice-compliant fashion. This has led to the initiation of several clinical trials using hPSC-derived cells to replace lost or dysfunctional cells, demonstrating evidence of both safety and efficacy. Here, we highlight successes from some of the hPSC-based trials reporting early signs of efficacy and discuss common challenges in clinical translation of cell therapies.</p>}}, author = {{Christiansen, Josefine Rågård and Kirkeby, Agnete}}, issn = {{0950-1991}}, keywords = {{ATMP; Cell therapy; Clinical trial; Human pluripotent stem cells; Transplantation}}, language = {{eng}}, number = {{7}}, publisher = {{The Company of Biologists Ltd}}, series = {{Development (Cambridge)}}, title = {{Clinical translation of pluripotent stem cell-based therapies : successes and challenges}}, url = {{http://dx.doi.org/10.1242/dev.202067}}, doi = {{10.1242/dev.202067}}, volume = {{151}}, year = {{2024}}, }